Claims for Patent: 10,537,572

Summary for Patent: 10,537,572

Title:	Methods of administering elagolix
Abstract:	The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.
Inventor(s):	Goss; Sandra L. (Wadsworth, IL), Klein; Cheri E. (Northbrook, IL), Ng; Juki Wing-Keung (Highland Park, IL), Salem; Ahmed (Libertyville, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	15/957,469
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,537,572
Patent Claims:	1. A method for treating endometriosis in a patient, the method comprising: orally administering to the patient once daily 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-ben- zyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl- ethylamino)-butyric acid as a sodium salt (elagolix), wherein the sodium salt is administered in an amount equivalent to 150 mg of the free acid; wherein the patient receives a single dose of 600 mg of rifampin, wherein maximum plasma concentration for elagolix is increased by 4.4 fold relative to administration of elagolix alone and wherein plasma area-under-the-curve for elagolix is increased by 5.6 fold relative to administration of elagolix alone. 2. A method for treating endometriosis in a patient, the method comprising: orally administering to the patient once daily 4-((R)-2[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benz- yl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl- ethylamino)-butyric acid as a sodium salt (elagolix), wherein the sodium salt is administered in an amount equivalent to 150 mg of the free acid; wherein the patient receives 600 mg of rifampin once daily, wherein maximum plasma concentration for elagolix is increased by 2.0 fold relative to administration of elagolix alone and wherein plasma area-under-the-curve for elagolix is increased by 1.65 fold relative to administration of elagolix alone.